Q-omics provides the consensus-scored MEIOB profile across patient tissues and cancer cell-line models. MEIOB expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MEIOB is differentially expressed in 7, with the highest sampling consensus in KICH. Additionally, MEIOB RNA expression shows 13,689 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, KICH, and TGCT as cancer lineages where MEIOB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MEIOB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MEIOB survival associations across molecular data types. MEIOB RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MEIOB RNA expression–survival associations across cancer types. High MEIOB expression shows unfavorable associations in ACC, UCEC and KIRC, but favorable associations in HNSC, SKCM and BLCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MEIOB RNA expression.
This table summarizes MEIOB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for MEIOB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MEIOB shows lower tumor expression in KICH and THCA and higher tumor expression in LUSC, BLCA, LUAD and KIRP. The KICH box plot shows higher MEIOB RNA expression in normal versus tumor tissue (log2 FC = −0.040, t-test p = .011).
This table shows molecular features associated with MEIOB in patient tissues and cancer cell lines. In patient samples, MEIOB shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MEIOB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
